Pulmatrix has announced that a recently completed Phase 1b study of its PUR0200 inhaled LAMA in COPD patients found that all three doses of PUR0200 produced significant improvement in lung function compared to placebo and comparable or greater to an active comparator. The company had announced initiation of the study in July 2013.
PUR0200 is a carrier-free dry powder created using the company’s iSPERSE particle engineering technology. According to the company, the carrier-free powder allowed for nominal doses that were only 20-50% as large as the lactose carrier formulation comparator. The study found that the lowest doses of PUR0200 produced plasma levels comparable to the comparator and proportional to the dose.
Pulmatrix Chief Scientific Officer David Hava commented, “The completion of our Phase 1b clinical trial with PUR0200 significantly expands our understanding of the PUR0200 formulation and sets a clear path for future development. The ability to match the pharmacodynamic and pharmacokinetic profile of the active comparator at significantly lower nominal doses highlights the potential of PUR0200 to bring meaningful benefit to patients. These data demonstrate the first clinical evidence of iSPERSE’s advantages over conventional lactose blend products. We are encouraged by the continued performance of PUR0200 and the iSPERSE platform and look forward to further advancing this program in 2014.”
Read the Pulmatrix press release.
